Roivant's Brepocitinib Achieves Clear or Almost Clear Skin in 69% of Cutaneous Sarcoidosis Patients in Phase 2 Trial

PUBT · 2d ago
Roivant's Brepocitinib Achieves Clear or Almost Clear Skin in 69% of Cutaneous Sarcoidosis Patients in Phase 2 Trial
  • Priovant announced publication of Phase 2 brepocitinib results in JAMA Dermatology, showing improved skin disease activity versus placebo in cutaneous sarcoidosis.
  • Patients also reported better skin-related quality of life; treatment was well tolerated over 16 weeks, with no serious adverse events.
  • Results will be presented at ACR Convergence 2026 today.
  • The findings support the ongoing Phase 3 BEACON+ trial, with topline data expected in 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611101324PRIMZONEFULLFEED9874714) on November 10, 2026, and is solely responsible for the information contained therein.